IgA vasculitis nephritis-outcomes in adult-onset disease.

IF 4.7 2区 医学 Q1 RHEUMATOLOGY Rheumatology Pub Date : 2025-02-01 DOI:10.1093/rheumatology/keae030
James Stanway, Nina Brown, Afeera Pervez, Els Van de Perre, James Tollitt, Nikolaos Marketos, Nikki Wong, Ajay Dhaygude, Arvind Ponnusamy, Ed O'Riordan, Michael Venning, Mårten Segelmark, Matthew Morgan, David Jayne, Patrick Hamilton, Charles D Pusey, Louise Oni, Alan D Salama
{"title":"IgA vasculitis nephritis-outcomes in adult-onset disease.","authors":"James Stanway, Nina Brown, Afeera Pervez, Els Van de Perre, James Tollitt, Nikolaos Marketos, Nikki Wong, Ajay Dhaygude, Arvind Ponnusamy, Ed O'Riordan, Michael Venning, Mårten Segelmark, Matthew Morgan, David Jayne, Patrick Hamilton, Charles D Pusey, Louise Oni, Alan D Salama","doi":"10.1093/rheumatology/keae030","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>IgA vasculitis (IgAV) in adults has been relatively under-investigated. Since outcomes are worse in other forms of vasculitis with increasing age, we investigated the outcomes of IgAV comparing younger adults (18-34), middle-aged adults (35-64) and elderly patients (≥64 years) focusing on kidney outcomes.</p><p><strong>Methods: </strong>We identified patients with renal biopsy-confirmed IgAV nephritis and collected data regarding clinical features and progression to end stage kidney disease (ESKD). The relationship between patient factors and ESKD was analysed by regression.</p><p><strong>Results: </strong>We identified 202 cases, 34% aged 18-34, 43% aged 35-64 and 23% elderly (>64 years). Median follow-up was 44 months. Elderly patients were more likely to present with ESKD (23.9%) compared with middle-aged (13.7%) and younger adults (2.9%) (χ2 11.6, P = 0.002). In patients with independent kidney function at biopsy, there was no difference in outcomes between age groups. Male gender, Black ethnicity, diabetes, histological evidence of chronic renal damage and estimated glomerular filtration rate < 30 ml/min were risk factors for development of ESKD. In this observational study 68.3% of patients received glucocorticoids and 56.9% additional immunosuppression.</p><p><strong>Conclusion: </strong>Elderly patients with IgAV are more likely to have ESKD at presentation, but there is no difference in renal survival between age groups, among those presenting with independent renal function. Renal impairment at biopsy is an independent risk factor for subsequent development of ESKD. There is significant variability in the timing of kidney biopsy and management of these patients among specialist centres. Young adults have outcomes more in keeping with childhood IgAV.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"690-696"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae030","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: IgA vasculitis (IgAV) in adults has been relatively under-investigated. Since outcomes are worse in other forms of vasculitis with increasing age, we investigated the outcomes of IgAV comparing younger adults (18-34), middle-aged adults (35-64) and elderly patients (≥64 years) focusing on kidney outcomes.

Methods: We identified patients with renal biopsy-confirmed IgAV nephritis and collected data regarding clinical features and progression to end stage kidney disease (ESKD). The relationship between patient factors and ESKD was analysed by regression.

Results: We identified 202 cases, 34% aged 18-34, 43% aged 35-64 and 23% elderly (>64 years). Median follow-up was 44 months. Elderly patients were more likely to present with ESKD (23.9%) compared with middle-aged (13.7%) and younger adults (2.9%) (χ2 11.6, P = 0.002). In patients with independent kidney function at biopsy, there was no difference in outcomes between age groups. Male gender, Black ethnicity, diabetes, histological evidence of chronic renal damage and estimated glomerular filtration rate < 30 ml/min were risk factors for development of ESKD. In this observational study 68.3% of patients received glucocorticoids and 56.9% additional immunosuppression.

Conclusion: Elderly patients with IgAV are more likely to have ESKD at presentation, but there is no difference in renal survival between age groups, among those presenting with independent renal function. Renal impairment at biopsy is an independent risk factor for subsequent development of ESKD. There is significant variability in the timing of kidney biopsy and management of these patients among specialist centres. Young adults have outcomes more in keeping with childhood IgAV.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IgA 血管炎肾炎--成人发病的结果。
目的:对成人 IgA 血管炎(IgAV)的研究相对较少。随着年龄的增长,其他形式的血管炎的预后会越来越差,因此我们对 IgAV 的预后进行了研究,比较了年轻成人(18-34 岁)、中年成人(35-64 岁)和老年患者(≥64 岁)的肾脏预后:我们确定了经肾活检证实的 IgAV 肾炎患者,并收集了有关临床特征和进展至终末期肾病(ESKD)的数据。通过回归分析了患者因素与 ESKD 之间的关系:我们共发现了 202 个病例,其中 34% 年龄在 18-34 岁之间,43% 年龄在 35-64 岁之间,23% 为老年人(大于 64 岁)。中位随访时间为 44 个月。与中年人(13.7%)和年轻人(2.9%)相比,老年患者更有可能出现 ESKD(23.9%)(χ2 11.6,P= 0.002)。在活检时肾功能独立的患者中,不同年龄组的结果没有差异。男性、黑人、糖尿病、慢性肾损伤组织学证据和 eGFR 结论:IgAV 老年患者在发病时更有可能患有 ESKD,但在有独立肾功能的患者中,不同年龄组的肾脏存活率没有差异。活检时的肾功能损害是随后发展为 ESKD 的独立风险因素。各专科中心在对这些患者进行肾活检和管理的时机上存在很大差异。青壮年患者的治疗结果与儿童 IgAV 更为相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Rheumatology
Rheumatology 医学-风湿病学
CiteScore
9.40
自引率
7.30%
发文量
1091
审稿时长
2 months
期刊介绍: Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.
期刊最新文献
Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in interstitial lung disease: A retrospective cohort study Abatacept and the risk of malignancy: a meta-analysis across disease indications Advancing treatment for idiopathic inflammatory myopathies: insights into immune modulation by JAK inhibition. Efficacy of upadacitinib in treating a paediatric case of refractory Takayasu arteritis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1